LeMaitre Vascular (NASDAQ:LMAT) Updates Q3 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its third quarter 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.420-0.460 for the period, compared to the consensus EPS estimate of 0.420. The company issued revenue guidance of $52.7 million-$54.7 million, compared to the consensus revenue estimate of $52.4 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.820-1.910 EPS.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Barrington Research upped their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an outperform rating in a research report on Friday, May 3rd. JMP Securities raised their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a research note on Friday, May 3rd. StockNews.com downgraded LeMaitre Vascular from a buy rating to a hold rating in a report on Thursday, July 25th. Roth Capital upgraded LeMaitre Vascular to a strong-buy rating in a research note on Friday, May 31st. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and raised their price target for the stock from $59.00 to $75.00 in a research report on Friday, April 26th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $77.57.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded down $0.64 during midday trading on Thursday, hitting $86.25. The company’s stock had a trading volume of 216,420 shares, compared to its average volume of 127,351. The firm has a market cap of $1.94 billion, a P/E ratio of 56.59, a P/E/G ratio of 2.68 and a beta of 0.89. LeMaitre Vascular has a 1-year low of $44.27 and a 1-year high of $91.76. The firm’s fifty day moving average price is $82.45 and its 200-day moving average price is $71.37.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The company had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. LeMaitre Vascular’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.27 earnings per share. As a group, research analysts predict that LeMaitre Vascular will post 1.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Bridget A. Ross sold 5,500 shares of the company’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $77.99, for a total transaction of $428,945.00. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at $177,661.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other LeMaitre Vascular news, Director David B. Roberts sold 5,025 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.62, for a total transaction of $379,990.50. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,067,300.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bridget A. Ross sold 5,500 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $77.99, for a total value of $428,945.00. Following the transaction, the director now directly owns 2,278 shares in the company, valued at $177,661.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,437 shares of company stock valued at $10,076,242. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.